| Total n = 1080 | No atherogenic dyslipidemia n = 1020 | Atherogenic dyslipidemia n = 60 | p |
---|---|---|---|---|
Clinical characteristics | ||||
 Age, years | 61.6 ± 9.0 | 61.7 ± 9.1 | 59.7 ± 8.2 | 0.09 |
 Gender, male/female | 614/466 | 577/443 | 37/23 | 0.44 |
 Body mass index, kg/m2 | 30.2 ± 5.9 | 30.2 ± 6.0 | 31.1 ± 4.9 | 0.23 |
 Waist circumference, cm | 104 ± 13 | 104 ± 13 | 107 ± 10 | 0.37 |
Diabetes | ||||
 Diabetes duration, years | 13.8 ± 8.5 | 13.9 ± 8.6 | 11.8 ± 6.9 | 0.07 |
 HbA1c, % | 8.5 ± 1.8 | 8.4 ± 1.8 | 8.6 ± 2.0 | 0.42 |
 HbA1c, mmol/mol | 69 ± 6 | 68 ± 6 | 70 ± 7 | 0.42 |
 Retinopathy, % | 357 (34.2) | 341 (34.7) | 16 (27.1) | 0.24 |
 Nephropathy, % | 406 (57.3) | 383 (57.5) | 23 (53.5) | 0.61 |
 Peripheral arterial occlusive disease, % | 119 (11.3) | 110 (11.1) | 9 (15.8) | 0.27 |
Additional cardiovascular risk factors | ||||
 Family history of premature CAD, % | 137 (13.0) | 126 (12.7) | 11 (19.0) | 0.16 |
 Hypertension, % | 402 (76.3) | 376 (76.3) | 26 (76.5) | 0.98 |
 Lipid parameters | ||||
  Total cholesterol, mmol/L | 4.5 ± 0.7 | 4.5 ± 0.7 | 4.7 ± 0.7 | <0.05 |
  HDL cholesterol, mmol/L | 1.3 ± 0.5 | 1.3 ± 0.5 | 0.8 ± 0.1 | <0.0001 |
  Triglycerides, mmol/L | 1.7 ± 1.0 | 1.6 ± 0.8 | 3.4 ± 1.1 | <0.0001 |
  LDL cholesterol, mmol/L | 2.4 ± 0.6 | 2.4 ± 0.6 | 2.4 ± 0.6 | 0.27 |
  Non HDL cholesterol, mmol/L | 3.2 ± 0.7 | 3.1 ± 0.7 | 3.9 ± 0.7 | <0.0001 |
  Apoprotein A1, g/L | 1.47 ± 0.74 | 1.49 ± 0.28 | 1.10 ± 0.12 | <0.0001 |
  Apoprotein B, g/L | 0.89 ± 0.18 | 0.89 ± 0.18 | 1.10 ± 0.12 | 0.06 |
  Fibrate treatment, % | 96 (9.1) | 87 (8.7) | 9 (15.8) | 0.09 |
  Statin treatment, % | 438 (41.4) | 415 (41.5) | 23 (40.4) | 0.87 |
 Smoking, % | 245 (22.8) | 226 (22.3) | 19 (32.2) | 0.08 |